Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,176 | -4,679 | -35,140 | -37,730 | -78,751 |
| Depreciation Amortization | 7 | 2 | 3,654 | 3,740 | 2,980 |
| Accounts receivable | 2 | -4 | 3 | 1,107 | 3,555 |
| Accounts payable and accrued liabilities | 97 | -100 | -773 | -25 | 274 |
| Other Working Capital | 473 | -729 | -6,254 | 870 | 2,789 |
| Other Operating Activity | 728 | 539 | 8,368 | 2,806 | 7,685 |
| Operating Cash Flow | $-2,869 | $-4,971 | $-30,142 | $-29,232 | $-61,468 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -98 | N/A | 1,346 | -193 | -3,323 |
| Investing Cash Flow | $-98 | $N/A | $1,346 | $-193 | $-3,323 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 25,000 |
| Debt Repayment | N/A | N/A | -18,105 | -8,333 | N/A |
| Common Stock Issued | 1,911 | N/A | 92 | 14,745 | 1,036 |
| Common Stock Repurchased | N/A | N/A | N/A | -45 | N/A |
| Other Financing Activity | 1,350 | 0 | -125 | 0 | -260 |
| Financing Cash Flow | $3,261 | $N/A | $-18,138 | $6,367 | $25,776 |
| Beginning Cash Position | 1,091 | 6,062 | 52,996 | 76,054 | 115,069 |
| End Cash Position | 1,385 | 1,091 | 6,062 | 52,996 | 76,054 |
| Net Cash Flow | $294 | $-4,971 | $-46,934 | $-23,058 | $-39,015 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,869 | -4,971 | -30,142 | -29,232 | -61,468 |
| Capital Expenditure | -98 | N/A | -197 | -216 | -3,323 |
| Free Cash Flow | -2,967 | -4,971 | -30,339 | -29,448 | -64,791 |